A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT03743246 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Absence of significant therapeutic benefit over existing therapies

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin

Interventions

DRUG: JCAR017
DRUG: Lymphodepleting
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Celgene